Drugs & Targets FDA grants accelerated approval to selpercatinib for pediatric RET-altered metastatic thyroid cancer or solid tumors May 31, 2024Vol.50 No.22
Drugs & Targets FDA acknowledges BLA resubmission for Zolbetuximab for HER2- gastric or GEJ adenocarcinoma with CLDN18.2-positive tumors May 31, 2024Vol.50 No.22
Drugs & Targets European Commission approves Opdivo combination for unresectable or metastatic UC May 31, 2024Vol.50 No.22
Drugs & Targets NHS England will wait to consider NHS rollout of Galleri multi-cancer early detection test May 31, 2024Vol.50 No.22
Drugs & Targets Estonia to develop personalized CAR T-cell therapy for blood cancer patients May 31, 2024Vol.50 No.22
Drugs & Targets Secarna, Orbit collaborate to develop peptide-conjugated targeted ASO therapeutics May 31, 2024Vol.50 No.22
Drugs & Targets Cartography, Gilead collaborate to develop therapies for breast and lung cancers May 31, 2024Vol.50 No.22
Drugs & Targets FDA advisory committee recommends approval of Shield blood test for colorectal cancer screening May 24, 2024Vol.50 No.21
Drugs & Targets FDA withdraws accelerated approval of infigratinib for metastatic cholangiocarcinoma with FGFR2 May 24, 2024Vol.50 No.21
